A phase I trial assessing the safety, pharmacokinetics, cerebrospinal fluid penetrance, and food effect of BTK inhibitor tolebrutinib in healthy volunteers by Marie‐José Cabanis, Olivier Nicolas, Olivier Vitse, Christelle Jan, Priscilla Brun, Patrick Soubayrol, William B. Smith, Timothy J. Turner, Emmanuel Krupka

Get full text